The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML).
Anjali S. Advani
No relevant relationships to disclose
Shannon McDonough
No relevant relationships to disclose
Edward Copelan
No relevant relationships to disclose
Cheryl L. Willman
No relevant relationships to disclose
Deborah A. Mulford
No relevant relationships to disclose
Alan F. List
No relevant relationships to disclose
Mikkael A. Sekeres
No relevant relationships to disclose
Megan Othus
No relevant relationships to disclose
Harry P. Erba
No relevant relationships to disclose
Frederick R. Appelbaum
No relevant relationships to disclose